Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivia Dean

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Journal of Psychiatry & Neuroscience : JPN|December 2, 2010
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionOlivia Dean, Frank Giorlando, Michael Berk
The International Journal of Neuropsychopharmacology|January 22, 2008
Oxidative stress in psychiatric disorders: evidence base and therapeutic implicationsFelicity Ng, Michael Berk, Olivia Dean, et al.
CNS Drugs|October 24, 2013
Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implicationsGeorge Anderson, Michael Berk, Olivia Dean, et al.
Trends in Pharmacological Sciences|June 10, 2008
Glutathione: a novel treatment target in psychiatryMichael Berk, Felicity Ng, Olivia Dean, et al.
Frontiers in Psychiatry|April 17, 2020
Studies on Haloperidol and Adjunctive α-Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male RatsJana Lotter, Marisa Möller, Olivia Dean, et al.
Current Neurovascular Research|May 24, 2014
Post-stroke depression therapy: where are we now?Seyed Fazel Nabavi, Alyna Turner, Olivia Dean, et al.
Expert Opinion on Biological Therapy|November 8, 2008
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utilitySeetal Dodd, Olivia Dean, David L Copolov, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's diseaseManfred Gerlach, Gerd D Bartoszyk, Peter Riederer, et al.
The Journal of ECT|November 26, 2024
Intravenous Ketamine to Facilitate Transport of Agitated Patients to the ECT ClinicOlivia Dean, Anthony Byford-Brooks, Kara Hannigan, et al.
Expert Opinion on Therapeutic Targets|October 20, 2010
Oxidative pathways as a drug target for the treatment of autismKristi-Ann Villagonzalo, Seetal Dodd, Olivia Dean, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Journal of Psychiatry & Neuroscience : JPN|December 2, 2010
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionOlivia Dean, Frank Giorlando, Michael Berk
The International Journal of Neuropsychopharmacology|January 22, 2008
Oxidative stress in psychiatric disorders: evidence base and therapeutic implicationsFelicity Ng, Michael Berk, Olivia Dean, et al.
CNS Drugs|October 24, 2013
Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implicationsGeorge Anderson, Michael Berk, Olivia Dean, et al.
Trends in Pharmacological Sciences|June 10, 2008
Glutathione: a novel treatment target in psychiatryMichael Berk, Felicity Ng, Olivia Dean, et al.
Frontiers in Psychiatry|April 17, 2020
Studies on Haloperidol and Adjunctive α-Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male RatsJana Lotter, Marisa Möller, Olivia Dean, et al.
Current Neurovascular Research|May 24, 2014
Post-stroke depression therapy: where are we now?Seyed Fazel Nabavi, Alyna Turner, Olivia Dean, et al.
Expert Opinion on Biological Therapy|November 8, 2008
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utilitySeetal Dodd, Olivia Dean, David L Copolov, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's diseaseManfred Gerlach, Gerd D Bartoszyk, Peter Riederer, et al.
The Journal of ECT|November 26, 2024
Intravenous Ketamine to Facilitate Transport of Agitated Patients to the ECT ClinicOlivia Dean, Anthony Byford-Brooks, Kara Hannigan, et al.
Expert Opinion on Therapeutic Targets|October 20, 2010
Oxidative pathways as a drug target for the treatment of autismKristi-Ann Villagonzalo, Seetal Dodd, Olivia Dean, et al.
Pageof 5